Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
Structure Therapeutics announced it will present data on its oral GLP-1RA aleniglipron and combination therapies at the American Diabetes Association 86th Scientific Sessions in June. The presentations include an oral session on the Phase 2b ACCESS trial and posters on dose-ranging and combination treatments with amylin receptor agonist ACCG-2671.
Key figures
- Drug Name
- Aleniglipron
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.